BioPorto A/S (THOXF)
| Previous close | 0.7500 |
| Open | 0.7500 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.7500 - 0.7500 |
| 52-week range | 0.6439 - 0.7500 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 251.01M |
| Beta (5Y monthly) | 1.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Strong Performance of The NGAL Test Drives Revenue Growth
May 11, 2022Announcement no. 11 Strong Performance of The NGAL Test Drives Revenue Growth Revenues totaled DKK 6.5 million in the first quarter of 2022, a 17% increase over the prior year. This growth was driven by a 70% increase in The NGAL Test sales, primarily from research use only (RUO) sales in the US and the timing of customer orders, which were up 116% over the prior year and a 10% increase in rest-of-the-world (ROW) sales of the test. ELISA kit revenue increased 138% in the first quarte
- GlobeNewswire
Grant of warrants
May 5, 2022Announcement no. 10 Grant of warrants The Board of Directors of BioPorto A/S (“BioPorto”) (Nasdaq: BIOPOR), in accordance with its current authorization to issue warrants to key employees of BioPorto, today issued 270,000 warrants for the subscription of an equal number of shares. The warrants are issued in accordance with the company’s remuneration policy and the authorization in section 18 a of the Articles of Association. Each warrant grants the holder the right to subscribe for on
- GlobeNewswire
BioPorto A/S - Annual General Meeting
April 28, 2022Announcement no. 9 BioPorto A/S - Annual General Meeting Today, BioPorto A/S held its Annual General Meeting. The general meeting resolved to conduct the meeting in English without simultaneous interpretation into Danish. Subsequently, the report on the Company’s activities was noted and the 2021 Annual Report was adopted, including the proposed allocation of the results. Discharge of liability was granted to the Board of Directors and the Executive Management, and the 2021 Remuner
